Cascadian Therapeutics Inc. is looking to raise approximately $82.5 million in two concurrent underwritten offerings.
The company priced an offering of 23,182,000 common stock at $3.30 apiece to raise $76.5 million; Cascadian will also issue 1,818 series E preferred stock at $3,300 per share to raise another $6 million.
Each series E preferred stock is convertible into 1,000 Cascadian shares. Underwriters have an option to purchase an additional 3,477,300 of the shares offered.
The offering is expected to close Jan. 27 and will help fund the clinical trial of Tucatinib for the treatment of breast cancer.
Cowen and Co. LLC and Barclays Capital Inc. are acting as joint book-running managers of the issue, with Raymond James & Associates Inc. acting as lead manager and BTIG LLC acting as a co-manager.